Academic Journals Database
Disseminating quality controlled scientific knowledge

Sorafenib in metastatic MTC – a case report and minireview of the literature

ADD TO MY LIST
 
Author(s): Mila Petrova | Zhasmina Mihaylova | Albena Fakirova

Journal: International Medical Case Reports Journal
ISSN 1179-142X

Volume: 2010;
Issue: default;
Start page: 55;
Date: 2010;
Original page

ABSTRACT
Mila Petrova1, Zhasmina Mihaylova1, Albena Fakirova21Hematology and Oncology Department, 2Pathology Department, Medical Military Academy, Sofia, BulgariaAbstract: Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.Keywords: medullary thyroid cancer, tumor response, cardiotoxicity, TKIs
Affiliate Program     

Tango Jona
Tangokurs Rapperswil-Jona